Last reviewed · How we verify
BGM0504 Administered SC — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
BGM0504 Administered SC (BGM0504 Administered SC) — BrightGene Bio-Medical Technology Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| BGM0504 Administered SC TARGET | BGM0504 Administered SC | BrightGene Bio-Medical Technology Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- BGM0504 Administered SC CI watch — RSS
- BGM0504 Administered SC CI watch — Atom
- BGM0504 Administered SC CI watch — JSON
- BGM0504 Administered SC alone — RSS
Cite this brief
Drug Landscape (2026). BGM0504 Administered SC — Competitive Intelligence Brief. https://druglandscape.com/ci/bgm0504-administered-sc. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing